Gossypol Acetate

Phase 2

PPeking University People's Hospital

Gossypol Acetate is one of 3 therapeutic programs targeting Advanced Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced Colorectal CancerNot yet recruiting

Advanced Colorectal CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

8 competitors in Advanced Colorectal Cancer

#DrugCompanyPhaseTrials

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 2

Ongericimab

SShanghai Junshi Bioscience Co., Ltd.

Phase 2

1 3

Gossypol Acetate

PPeking University People's Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Not yet recruiting

Advanced Colorectal Cancer

NCT07656766

Clinical

Trials by Indication[1]

Advanced Colorectal Cancer1 trial

A Single-Arm, Open-Label, Exploratory Phase II Clinical Trial of Sintilimab Plus Gossypol Acetate in Patients With Advanced pMMR/MSS Colorectal Cancer After Failure of at Least Two Prior Lines of Therapy

Not yet recruiting·PPeking University People's Hospital·Phase 2·NCT07656766·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gossypol Acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Gossypol Acetate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Peking University People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: PPeking University People's Hospital

Gossypol Acetate

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Advanced Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News